Acumen Pharmaceuticals, Inc. (ABOS) Institutional Ownership

Ownership Summary

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) has 71 institutional investors with active 13F positions as of December 2025.

• These investors collectively held 61.8% of Acumen Pharmaceuticals's outstanding shares in December 2025, up from 60.6% in September 2025.
• Their total shares held in ABOS increased 2.38% quarter over quarter, and separately, investors owning Acumen Pharmaceuticals decreased 10.13% from a year ago.
• Of these 71 holders, 26 added to their stakes in Acumen Pharmaceuticals, 23 trimmed positions, and 22 made no changes.
• The aggregate institutional position in Acumen Pharmaceuticals amounted to 37.42Mn shares as of December 2025, up by 868.58K shares quarter on quarter, and down 5.54Mn shares year over year.
• RA CAPITAL MANAGEMENT, L.P. is the top holder of Acumen Pharmaceuticals as of December 31, 2025, with 20.99Mn shares representing 34.66% of outstanding stock.
• Leading buyers of Acumen Pharmaceuticals shares for the quarter ending December 2025 were RA CAPITAL MANAGEMENT, L.P. (6.06Mn), Alyeska Investment Group, L.P. (1.52Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.51Mn), Ikarian Capital, LLC (799.48K), TWO SIGMA INVESTMENTS, LP (387.59K).
• The largest sellers of Acumen Pharmaceuticals for the quarter ending December 2025 were Laurion Capital Management LP (1.21Mn), FMR LLC (870.15K), JANE STREET GROUP, LLC (52.46K), Goldman Sachs Group Inc (29.02K), Morgan Stanley (22.32K).
• Per Business Quant, the top 10 investors in ABOS for the quarter ending December 2025 include RA CAPITAL MANAGEMENT, L.P. (20.99Mn), Sands Capital Alternatives, LLC (3.72Mn), Alyeska Investment Group, L.P. (2.45Mn), Franklin Resources Inc (2.31Mn), ADAR1 Capital Management, LLC (2.16Mn), Knollwood Investment Advisory, LLC (1.63Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.51Mn), FMR LLC (1.16Mn), Ikarian Capital, LLC (1.05Mn), Hudson Bay Capital Management LP (968.94K).